Clinical effect of Zhonggu granules combined with governor vessel moxibustion in the treatment of ankylosing spondylitis

doi:10.3760/cma.j.issn.1007-1245.2024.18.008

Abstract

Abstract:

Objective　To evaluate the clinical efficacy of Zhonggu granules combined with governor vessel moxibustion in the treatment of ankylosing spondylitis. Methods　A total of 128 patients with ankylosing spondylitis admitted to Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from January 2022 to August 2023 were selected and were divided into an experimental group and a control group by coin tossing, with 64 cases in each group. In the control group, there were 33 males and 31 females, aged (34.89±8.21) years, and the course of disease was (8.29±4.63) years. In the experimental group, there were 32 males and 32 females, aged (34.56±8.43) years, and the course of disease was (8.34±4.57) years. The control group received conventional drug treatment, oral salazosulfapyridine enteric-coated tablets (1.0 g each time, twice a day) + celecoxib capsules (0.2 g each time, once a day). The experimental group received Zhonggu granules (10 g each time, twice a day, infused with warm water) combined with governor vessel moxibustion (100 min each time, once a week). The treatment course was 3 months. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Function Index (BASFI), traditional Chinese medicine (TCM) symptom score, inflammatory polarization indicators [M1 macrophage CD86 expression, M2 macrophage CD16 expression, matrix metalloproteinase 3 (MMP-3), and tumor necrosis factor (TNF)-α], bone metabolism indicators [N-terminal propeptide of type I procollagen (PINP), serum β-C-terminal telopeptide of type I collagen (β-CTX), and bone-specific alkaline phosphatase (BALP)], physical examination indicators (finger-to-floor distance, chest expansion, and occiput-to-wall distance), and clinical efficacy were compared between the two groups. Statistical methods included t test and χ² test. Results　After 3 months of treatment, the BASDAI, BASFI, and TCM symptom score of the experimental group were (2.82±0.40) points, (3.38±0.48) points, and (2.91±0.34) points, which were lower than those of the control group [(4.05±0.58) points, (4.26±0.61) points, and (4.64±0.66) points], with statistically significant differences (t=13.966, 9.070, and 18.642, all P<0.001). There were statistically significant differences in the M1 macrophage CD86 expression, M2 macrophage CD16 expression, and levels of MMP-3, TNF-α, PINP, β-CTX, and BALP between the two groups (t=2.761, 4.094, 4.245, 9.505, 4.056, 3.536, and 4.356, all P<0.05). The finger-to-floor distance, chest expansion, and occiput-to-wall distance of the experimental group were (16.24±3.04) cm, (5.11±0.94) cm, and (2.76±1.05) cm, and those of the control group were (22.39±3.15) cm, (4.42±1.08) cm, and (4.02±1.21) cm, with statistically significant differences (t=11.239, 3.855, and 6.292, all P<0.001). The total effective rate of the experimental group was higher than that of the control group [93.75% (60/64) vs. 79.68% (51/64)], with a statistically significant difference (χ²=5.494, P=0.019). Conclusion　Zhonggu granules combined with governor vessel moxibustion in the treatment of ankylosing spondylitis can effectively reduce the BASDAI and BASFI, alleviate the TCM symptoms, regulate the inflammatory polarization and bone metabolism indexes, and improve the physical examination indexes, proving to be a safe and effective treatment method.

Key words:

Ankylosing spondylitis, Zhonggu granules, Governor vessel moxibustion, Inflammation polarization, Bone metabolism

摘要：

目的　评估重骨颗粒结合督脉灸治疗强直性脊柱炎患者的临床疗效。方法　选取2022年1月至2023年8月陕西中医药大学附属医院收治的128例强直性脊柱炎患者，通过掷硬币法将患者分为试验组和对照组，每组64例。对照组男33例，女31例，年龄（34.89±8.21）岁，病程（8.29±4.63）年。试验组男32例，女32例，年龄（34.56±8.43）岁，病程（8.34±4.57）年。对照组接受常规药物治疗，口服柳氮磺吡啶肠溶片（每次1.0 g，每日2次）+塞来昔布胶囊（每次0.2 g，每日1次）。试验组接受重骨颗粒（每次10 g，每日2次，温水冲服）结合督脉灸（每次持续100 min，1次/周）治疗。两组疗程均为3个月。对比两组的Bath强直性脊柱炎疾病活动指数（BASDAI）及Bath强直性脊柱炎功能指数（BASFI）、中医症状评分、炎症极化指标［M1型巨噬细胞CD86、M2型巨噬细胞CD16表达、基质金属蛋白酶3（MMP-3）、肿瘤坏死因子（TNF）-α］、骨代谢指标［Ⅰ型前胶原氨基端前肽（PINP）、血清β胶原降解产物（β-CTX）、骨特异性碱性磷酸酶（BALP）］、体征指标（指地距、胸廓扩展度、枕墙距）、临床疗效。统计学方法采用t检验、χ²检验。结果　治疗3个月后，试验组的BASDAI、BASFI、中医症状评分分别为（2.82±0.40）分、（3.38±0.48）分、（2.91±0.34）分，均低于对照组的（4.05±0.58）分、（4.26±0.61）分、（4.64±0.66）分，差异均有统计学意义（t=13.966、9.070、18.642，均P<0.001）；两组M1型巨噬细胞CD86、M2型巨噬细胞CD16、MMP-3、TNF-α、PINP、β-CTX、BALP水平比较，差异均有统计学意义（t=2.761、4.094、4.245、9.505、4.056、3.536、4.356，均P<0.05）；试验组的指地距、胸廓扩展度、枕墙距分别为（16.24±3.04）cm、（5.11±0.94）cm、（2.76±1.05）cm，对照组分别为（22.39±3.15）cm、（4.42±1.08）cm、（4.02±1.21）cm，差异均有统计学意义（t=11.239、3.855、6.292，均P<0.001）；试验组的临床治疗总有效率高于对照组［93.75%（60/64）比79.68%（51/64）］，差异有统计学意义（χ²=5.494，P=0.019）。结论　重骨颗粒结合督脉灸治疗强直性脊柱炎，能有效降低BASDAI、BASFI评分，减轻中医症状，调节炎症极化和骨代谢指标，改善体征指标，证明其为一种安全有效的治疗方法。

关键词:

强直性脊柱炎, 重骨颗粒, 督脉灸, 炎症极化, 骨代谢

Chen Kun, Shi Lei, Yang Feng.

Clinical effect of Zhonggu granules combined with governor vessel moxibustion in the treatment of ankylosing spondylitis [J]. International Medicine and Health Guidance News, 2024, 30(18): 3028-3033.

陈坤师磊杨锋.

重骨颗粒结合督脉灸治疗强直性脊柱炎患者的临床效果 [J]. 国际医药卫生导报, 2024, 30(18): 3028-3033.

References

[1] 束龙武,庞利君,李云飞,等. 重骨颗粒治疗肝肾亏虚型膝骨关节炎临床疗效及对骨代谢指标的影响[J]. 安徽中医药大学学报,2023,42(1):31-35. DOI:10.3969/j.issn.2095-7246. 2023.01.009.
[2] 万磊,刘健,黄传兵,等. 新风胶囊治疗强直性脊柱炎随机对照研究[J]. 中国中西医结合杂志,2022,42(10):1161-1168. DOI:10.7661/j.cjim.20211231.391.
[3] 周星宇,王新义,张玉飞,等. 间接灸联合补肾祛瘀通督丸治疗强直性脊柱炎的疗效观察[J]. 上海针灸杂志,2023,42(3):289-293. DOI:10.13460/j.issn.1005-0957.2023.03.0289.
[4] 陈君洁,尚双双,李明,等. 重骨颗粒对膝骨关节炎IL-17、IL-35细胞因子及软骨基质代谢的影响[J]. 中国骨质疏松杂志,2023,29(3):397-402. DOI:10.3969/j.issn.1006- 7108.2023.03.016.
[5] 凌春生,曾密,王冠,等. 督脉灸联合腹针治疗强直性脊柱炎临床观察[J]. 广西中医药大学学报,2020,23(3):1-4. DOI:10.3969/j.issn.2095-4441.2020.03.002.
[6] 中华医学会风湿病学分会.强直性脊柱炎诊断及治疗指南[J].中华风湿病学杂志,2010,14(8):557-559.DOI:10.3760/cma.j.issn.1007-7480.2010.08.012.
[7] 北京中西医结合学会风湿病专业委员会.强直性脊柱炎长期管理专家共识(2021年)[J].中国中西医结合杂志,2021,41(12):1426-1434.DOI:10.7661/cjim.20210730.373.
[8] 王培,柳杨,安艳辰,等. 雷火灸联合西药治疗肾虚督寒型强直性脊柱炎临床研究[J]. 陕西中医,2023,44(6):789-793. DOI:10.3969/j.issn.1000-7369.2023.06.025.
[9] 罗小光,张雪珍,黄翠婵. 短刺傍刺温针灸联合雷公藤多苷片治疗强直性脊柱炎急性发作疗效观察[J]. 现代中西医结合杂志,2022,31(15):2121-2125. DOI:10.3969/j.issn.1008-8849.2022.15.015.
[10] 中华人民共和国卫生部.中药新药临床研究指导原则试行[M].北京: 中国医药科技出版社,2002: 361-390.
[11] 郑筱萸.中药新药临床研究指导原则(试行)[S].北京: 中国医药科技出版社,2002:119-123.
[12] 胡植双,王健美,赵岩亮. 超声指标联合Framingham评分对强直性脊柱炎患者心血管受累风险的预测价值[J]. 河北医科大学学报,2023,44(8):952-955,966. DOI:10.3969/j.issn.1007-3205.2023.08.015.
[13] 于翱瑞,曹亚飞,林文平,等. 强直性脊柱炎患者外周血不同类型单核细胞极化与病情严重程度的关系[J]. 中国现代医学杂志,2023,33(24):74-79. DOI:10.3969/j.issn.1005- 8982.2023.24.013.
[14] Weinstein CLJ, Meehan AG, Lin J, et al. Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis[J]. Clinical Rheumatology, 2023, 42(12): 3397-3405. DOI: 10.1007/s10067-023-06760-z.
[15] 刘冰川,姬洪全,周方,等. 手术治疗伴有强直性脊柱炎的创伤性胸腰椎骨折的临床疗效[J]. 国际骨科学杂志,2020,41(4):243-247. DOI:10.3969/j.issn.1673-7083.2020. 04.012.
[16] 俞佳,汪悦,甘可,等. 汪悦治疗强直性脊柱炎经验[J]. 辽宁中医杂志,2020,47(11):58-60. DOI:10.13192/j.issn.1000- 1719.2020.11.015.
[17] Gourzoulidis G, Solakidi A, Psarra M, et al. Cost effectiveness of tofacitinib for the treatment of active ankylosing spondylitis in Greece[J]. Clinical Drug Investigation, 2024, 44(1): 59-69. DOI: 10.1007/s40261-023-01333-z.
[18] 程鹏,朱琦,姜婷,等. TNF-α拮抗剂对传统治疗反应欠佳的强直性脊柱炎患者生活质量的影响[J]. 中华全科医学,2020,18(3):384-387,431. DOI:10.16766/j.cnki.issn.1674- 4152.001253.
[19] 黄小凤,邱明山.揿针治疗强直性脊柱炎的临床体会[J].中医药通报,2023,22(02):66-67,70.DOI:10.14046/j.cnki.zyytb2002.2023.02.004.
[20] 吴承钧,汪海东. 温肾化瘀除痹汤联合TNF-α拮抗剂治疗强直性脊柱炎的临床观察[J]. 中国中医药科技,2023,30(3):557-559.
[21] 张硕,温博,杨芮姗. 益肾通督方治疗强直性脊柱炎临床疗效及相关机制初步探讨[J]. 天津中医药,2023,40(7):825-831. DOI:10.11656/j.issn.1672-1519.2023.07.02.
[22] 李志,马建武,杨建成,等. 经皮长节段固定治疗强直性脊柱炎合并骨折的疗效观察[J]. 颈腰痛杂志,2023,44(3):466-468. DOI:10.3969/j.issn.1005-7234.2023.03.044.
[23] Binh BH, Trung NN, Hung NV, et al. Current status of biological treatment in ankylosing spondylitis patients and some related factors[J]. Materia Socio-Medica, 2023, 35(3): 222-227. DOI: 10.5455/msm.2023.35.222-227.
[24] 薛秋倩,熊甚,郑宝林. 强直一方联合安健宁治疗湿热痹阻型强直性脊柱炎的临床观察[J]. 广州中医药大学学报,2023,40(7):1649-1654. DOI:10.13359/j.cnki.gzxbtcm. 2023.07.011.
[25] 叶磊, 邹一超, 张凯维. 温针灸联合关节腔内注射玻璃酸钠治疗强直性脊柱炎髋关节病变的临床研究[J]. 针灸推拿医学(英文版),2022,20(3):206-212.
[26] 侯堃,张秦,邵培培,等.益肾通督合剂结合督脉灸对强直性脊柱炎患者疗效及腰椎功能、免疫功能的影响[J].辽宁中医杂志,2022,49(1):146-149.DOI:10.13192/j.issn.1000- 1719.2022.01.042.
[27] 王亚渭,陈军,张春涛.督脉排针法治疗肾虚督寒型强直性脊柱炎的临床疗效及对辅助性T淋巴细胞17、辅助性T淋巴细胞1、肌酸激酶、蓬乱蛋白Dsh同源物2蛋白的影响[J].河北中医,2020,42(6):912-916.DOI:10.3969/j.issn.1002-2619.2020.06.024.
[28] 叶雪英,马春杰,苏淑仪,等. 逐经督脉灸疗法对肾虚督寒型的强直性脊柱炎患者肠道微生物和肠黏膜免疫反应的影响[J]. 临床和实验医学杂志,2019,18(3):270-274. DOI:10.3969/j.issn.1671-4695.2019.03.013.
[29] 汤忠富,尚双双,陈君洁,等. 重骨颗粒对强直性脊柱炎患者疾病活动及骨代谢的影响[J]. 中国骨质疏松杂志,2023,29(5):641-646. DOI:10.3969/j.issn.1006-7108.2023. 05.004.
[30] 滕金艳,周仲瑜,丁德光,等. 督脉灸联合补肾祛瘀针法治疗强直性脊柱炎急性发作疗效观察[J]. 针灸临床杂志,2021,37(3):22-26. DOI:10.19917/j.cnki.1005-0779.021049.